| Wang, Lu |
NCT05554965: Endoscopic Hemostatic and Sedative Treatment of Esophageal and Gastric Variceal Bleeding |
|
|
| Recruiting | 4 | 60 | RoW | Propofol, Active Comparator, Remimazolam besylate, Experimental | Renmin Hospital of Wuhan University | Endoscopic Hemostasis, Sedation | 10/22 | 12/22 | | |
| Recruiting | 4 | 1000 | RoW | protective ventilation, prone position ventilation, glucocorticoid therapy, Dexamethasone, Hydrocortisone, restrictive fluid resuscitation, Thymosin Alpha, Muscle relaxant therapy, Vecuronium Bromide, Succinylcholine, Integrated Chinese and Western Medicine Treatment, statin therapy, Simvastatin, Rosuvastatin, anti-infective treatment, Extracorporeal Membrane Oxygenation（ECMO）, stem cell therapy, Sedative analgesia/muscle relaxant therapy, Propofol, midazolam, dexmedetomidine, inotropes therapy, Dopamine, Olprinone, Levosimendan, Vasoactive drug therapy, Norepinephrine, epinephrine, metaraminol, isoproterenol | Second Affiliated Hospital, School of Medicine, Zhejiang University, Renmin Hospital of Wuhan University, The Second Affiliated Hospital of Harbin Medical University, West China Hospital, The First Affiliated Hospital of Zhengzhou University, Peking Union Medical College Hospital, Wuhan Union Hospital, China, Fudan University, Guangdong Provincial People's Hospital, Ningbo No. 1 Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University | Acute Respiratory Distress Syndrome | 10/23 | 12/23 | | |
NCT05673824: Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies. |
|
|
| Recruiting | 4 | 53 | RoW | Huaier Granule, VEGFR-TKIs | Fudan University, LinkDoc Technology (Beijing) Co. Ltd. | Nephrotoxicity | 02/25 | 04/25 | | |
NCT04162119: Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 2 | 30 | RoW | BCMA-PD1-CART Cell | Chinese PLA General Hospital | Multiple Myeloma | 10/21 | 10/22 | | |
NCT05254847: Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC |
|
|
| Recruiting | 2 | 75 | RoW | Capecitabine combined with lenvatinib and tislelizumab | Fudan University | Biliary Tract Cancer | 12/22 | 12/24 | | |
NCT05311319: HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection |
|
|
| Recruiting | 2 | 70 | RoW | HAIC+TQB2450+Anlotinib | Fudan University | Hepatocarcinoma | 12/22 | 12/23 | | |
NCT04996446: ALPPS Combined With Tislelizumab in Liver Malignancy |
|
|
| Recruiting | 2 | 20 | RoW | Tislelizumab, ALPPS surgery | Fudan University | Liver Malignant Tumors | 08/23 | 08/23 | | |
NCT05442632: Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy |
|
|
| Recruiting | 2 | 96 | RoW | Hetrombopag, Placebo | Fudan University | Hepatopathy | 12/25 | 12/25 | | |
| Recruiting | 2 | 42 | RoW | Multifocal Stereotactic Radiotherapy, Atezolizumab Injection [Tecentriq], Bevacizumab | Fudan University, Roche Pharma AG | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
NCT06285019: Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 65 | RoW | TOMOX-HAIC, Sintilimab, Bevacizumab | Fudan University | Hepatocellular Carcinoma | 12/24 | 12/25 | | |
NCT05435313: Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy |
|
|
| Active, not recruiting | 2 | 39 | RoW | HAIC, Fruquintinib, Tislelizumab, Raltitrexed, Oxaliplatin, Irinotecan | Fudan University | Colorectal Cancer | 01/24 | 02/24 | | |
NCT05753163: Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study |
|
|
| Recruiting | 2 | 44 | RoW | HAIC-FOLFOX combined with Sintilimab and Regorafenib | Fudan University | Colorectal Liver Metastasis | 03/24 | 03/25 | | |
NCT06441019: Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 42 | RoW | HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab | Fudan University | Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab | 05/25 | 05/26 | | |
NCT06475287: HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 42 | RoW | HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450 | Fudan University | Hepatocellular Carcinoma | 07/25 | 07/26 | | |
NCT05668884: GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma |
|
|
| Recruiting | 2 | 35 | RoW | Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab | Fudan University | Biliary Tract Carcinoma | 09/24 | 03/25 | | |
NCT05757336: Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab | Lu Wang, MD, PhD | Gallbladder Cancer, Initially Unresectable, the First Line Treatment | 12/24 | 12/26 | | |
NCT04979663: GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer |
|
|
| Recruiting | 1/2 | 10 | RoW | Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab | Fudan University | Biliary Tract Carcinoma | 06/22 | 06/22 | | |
NCT05643417: Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy |
|
|
| Not yet recruiting | 1 | 80 | RoW | HAIC、Bevacizumab、Camrelizumab, Camrelizumab brand name: ai rui ka; Bevacizumab brand name: ai rui tuo | Fudan University | Metastatic Liver Cancer | 10/23 | 10/24 | | |
NCT05771025: Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases |
|
|
| Recruiting | N/A | 55 | RoW | Hepatectomy | Fudan University | Nasopharyngeal Carcinoma, Liver Metastases | 12/23 | 12/25 | | |
| Recruiting | N/A | 122 | RoW | HHB+TAPB+and LA, HHB+LA, TAPB+LA | Lu Wang | Regional Anesthesia, Pain Control, Microwave Ablation, Liver Tumors | 12/23 | 12/23 | | |
| Recruiting | N/A | 366 | RoW | Cardiopulmonary rehabilitation, Usual care | The First Affiliated Hospital with Nanjing Medical University | Critical Illness | 06/25 | 12/25 | | |
NCT04996459: Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Active, not recruiting | N/A | 40 | RoW | Tislelizumab | Fudan University | Hepatocellular Carcinoma | 06/21 | 06/22 | | |
| Chen, Jindong |
NCT06166082: Stanford Neuromodulation Therapy (SNT) for the Treatment-Resistant Depression |
|
|
| Recruiting | N/A | 130 | RoW | Active iTBS-DLPFC, Sham iTBS-DLPFC | Changping Laboratory, Xianyue Hospital, Xiamen, Hebei Mental Health Center, Baoding, HuiLongGuan Hospital, Beijing, Wuhan Mental Health Center, Wuhan, Zhumadian Second People's Hospital, Zhumadian | Treatment Resistant Depression | 07/24 | 10/24 | | |
NCT05976009: pBFS-Guided rTMS Therapy Over Different Targets for Treatment-Resistant Depression |
|
|
| Recruiting | N/A | 80 | RoW | active rTMS stimulating | Changping Laboratory | Major Depressive Disorder, Treatment Resistant Depression, MDD | 08/24 | 09/24 | | |
